BRIEF-Atossa Therapeutics Streamlines Evangeline Breast Cancer Clinical Trial To Prioritize For 2026 NDA-Enabling Activities

Reuters

Oct 06, 2025

BRIEF-Atossa <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Streamlines Evangeline Breast Cancer Clinical Trial To Prioritize For 2026 NDA-Enabling Activities

Oct 6 (Reuters) - Atossa Therapeutics Inc ATOS.O:

ATOSSA THERAPEUTICS STREAMLINES EVANGELINE BREAST CANCER CLINICAL TRIAL TO PRIORITIZE FOR 2026 NDA-ENABLING ACTIVITIES
ATOSSA THERAPEUTICS INC - CHANGES EXPECTED TO REDUCE STUDY COSTS AND ACCELERATE READOUTS
ATOSSA THERAPEUTICS INC - FOCUSES ON NDA-ENABLING ACTIVITIES FOR INVESTIGATIONAL $(Z)$-ENDOXIFEN IN 2026
ATOSSA THERAPEUTICS INC - EVANGELINE STUDY PATIENT TOTAL REDUCED TO 40-65
ATOSSA THERAPEUTICS - NO CHANGE TO PATIENT SAFETY DATA COLLECTION OR DATA SAFETY MONITORING COMMITTEE OVERSIGHT BY THIS AMENDMENT

Source text: ID:nPn5DxbwHa

Further company coverage: ATOS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2573729156"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573729156\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573729156?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573729156","market":"nz","top_or_hot":-1,"title":"BRIEF-Atossa Therapeutics Streamlines Evangeline Breast Cancer Clinical Trial To Prioritize For 2026 NDA-Enabling Activities","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Atossa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Streamlines Evangeline Breast Cancer Clinical Trial To Prioritize For 2026 NDA-Enabling Activities</title></head><body><p><span>Oct 6 (Reuters)</span><span> - </span>Atossa Therapeutics Inc <span>ATOS.O</span>:</p><ul><li><p>ATOSSA THERAPEUTICS STREAMLINES EVANGELINE BREAST CANCER CLINICAL TRIAL TO PRIORITIZE FOR 2026 NDA-ENABLING ACTIVITIES</p></li><li><p>ATOSSA THERAPEUTICS INC - CHANGES EXPECTED TO REDUCE STUDY COSTS AND ACCELERATE READOUTS</p></li><li><p>ATOSSA THERAPEUTICS INC - FOCUSES ON NDA-ENABLING ACTIVITIES FOR INVESTIGATIONAL <a href=\"https://laohu8.com/S/Z\">$(Z)$</a>-ENDOXIFEN IN 2026</p></li><li><p>ATOSSA THERAPEUTICS INC - EVANGELINE STUDY PATIENT TOTAL REDUCED TO 40-65</p></li><li><p>ATOSSA THERAPEUTICS - NO CHANGE TO PATIENT SAFETY DATA COLLECTION OR DATA SAFETY MONITORING COMMITTEE OVERSIGHT BY THIS AMENDMENT</p></li></ul><p>Source text: <span>ID:nPn5DxbwHa</span></p><p>Further company coverage: <span>ATOS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Atossa Therapeutics Streamlines Evangeline Breast Cancer Clinical Trial To Prioritize For 2026 NDA-Enabling Activities</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Atossa Therapeutics Streamlines Evangeline Breast Cancer Clinical Trial To Prioritize For 2026 NDA-Enabling Activities\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-06 20:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Atossa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Streamlines Evangeline Breast Cancer Clinical Trial To Prioritize For 2026 NDA-Enabling Activities</title></head><body><p><span>Oct 6 (Reuters)</span><span> - </span>Atossa Therapeutics Inc <span>ATOS.O</span>:</p><ul><li><p>ATOSSA THERAPEUTICS STREAMLINES EVANGELINE BREAST CANCER CLINICAL TRIAL TO PRIORITIZE FOR 2026 NDA-ENABLING ACTIVITIES</p></li><li><p>ATOSSA THERAPEUTICS INC - CHANGES EXPECTED TO REDUCE STUDY COSTS AND ACCELERATE READOUTS</p></li><li><p>ATOSSA THERAPEUTICS INC - FOCUSES ON NDA-ENABLING ACTIVITIES FOR INVESTIGATIONAL <a href=\"https://laohu8.com/S/Z\">$(Z)$</a>-ENDOXIFEN IN 2026</p></li><li><p>ATOSSA THERAPEUTICS INC - EVANGELINE STUDY PATIENT TOTAL REDUCED TO 40-65</p></li><li><p>ATOSSA THERAPEUTICS - NO CHANGE TO PATIENT SAFETY DATA COLLECTION OR DATA SAFETY MONITORING COMMITTEE OVERSIGHT BY THIS AMENDMENT</p></li></ul><p>Source text: <span>ID:nPn5DxbwHa</span></p><p>Further company coverage: <span>ATOS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATOS","symbol_name":"Atossa Genetics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nTUA73NFWC:1","article_id":"2573729156","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573729156","pubTimestamp":1759753450,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Atossa Therapeutics Streamlines Evangeline Breast Cancer Clinical Trial To Prioritize For 2026 NDA-Enabling ActivitiesOct 6 (Reuters) - Atossa Therapeutics Inc ATOS.O:ATOSSA THERAPEUTICS STREAML","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATOS":"Atossa Genetics Inc","BK4139":"生物科技"},"translate_title":"简介-Atossa Therapeutics简化Evangeline乳腺癌临床试验，优先考虑2026年NDA支持活动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATOS":0.9},"content_text":"BRIEF-Atossa Therapeutics Streamlines Evangeline Breast Cancer Clinical Trial To Prioritize For 2026 NDA-Enabling ActivitiesOct 6 (Reuters) - Atossa Therapeutics Inc ATOS.O:ATOSSA THERAPEUTICS STREAMLINES EVANGELINE BREAST CANCER CLINICAL TRIAL TO PRIORITIZE FOR 2026 NDA-ENABLING ACTIVITIESATOSSA THERAPEUTICS INC - CHANGES EXPECTED TO REDUCE STUDY COSTS AND ACCELERATE READOUTSATOSSA THERAPEUTICS INC - FOCUSES ON NDA-ENABLING ACTIVITIES FOR INVESTIGATIONAL $(Z)$-ENDOXIFEN IN 2026ATOSSA THERAPEUTICS INC - EVANGELINE STUDY PATIENT TOTAL REDUCED TO 40-65ATOSSA THERAPEUTICS - NO CHANGE TO PATIENT SAFETY DATA COLLECTION OR DATA SAFETY MONITORING COMMITTEE OVERSIGHT BY THIS AMENDMENTSource text: ID:nPn5DxbwHaFurther company coverage: ATOS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}